LIST OF PATENTS (Registered)
1. Biomarker pnck for predicting effect of a dual-targeting agent, US10578621, Reg. Date 2020.03.03
2. Polypeptide, Anti-VEGF Antibody, and Anti-c-Met/Anti-VEGF Bispecific Antibodies comprising the same, US10246507, Reg. Date 2019.04.02
3. Combination therapy using c-Met inhibitor and IGF-1R inhibitor for c-Met inhibitor resistant cancers, US10064939, Reg. Date 2018.09.04
4. Biomarker Hsp90 for predicting effect of a c-Met inhibitor, US9956244, Reg. Date 2018.05.01
5. Combination therapy using dual inhibitor of c-MET and EGFR and IGF-1R inhibitor, US9943596, Reg. Date 2018.04.17
6. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases, US9931400, Reg. Date 2018.04.03
7. Anti-cancer peptide sequences, KR1018153220000, Reg. Date 2017.12.28
8. Anti-c-Met/anti-Ang2 bispecific antibody, US9808507, Reg. Date 2017.11.07
9. Method of combination therapy using an anti-C-Met antibody, US9717715, Reg. Date 2017.08.01
10. Method of combination therapy using an EGFR antagonist and anti-c-Met antibody, US9572878, Reg. Date 2017.02.21
11. Combination therapy for the treatment of cancer using an anti-C-met antibody, US9567641, Reg. Date 2017.02.14
12. Combination therapy using c-Met inhibitor and c-Myc inhibitor, US9457043, Reg. Date 2016.10.04
13. Combination therapy using c-Met inhibitor and beta-catenin inhibitor, US9457081, Reg. Date 2016.10.04
14. Method of treating solid cancers using anti-c-Met antibody and sorafenib combination therapy, US9233155, Reg. Date 2016.01.12
15. Use of Cbl as biomarker for identifying subject suitable for treatment with anti-c-Met antibody, US9213031, Reg. Date 2015.12.15
16. Use of LRIG1 as a biomarker for identifying a subject for application of anti-c-Met antibodies, US9213032, Reg. Date 2015.12.15
17. Method of treating cancer using anti-c-Met antibody and FGFR inhibitor combination therapy, US9192666, Reg. Date 2015.11.24
18. Anti-cancer drug screening method using RORalpha, US8697366, Reg. Date 2014.04.15
LIST OF PATENTS (Applied)
1. 10-2023-0098780 (2023. 07.28) 히스톤 코드 리더 도메인을 포함하는 폴리펩타이드 및 이의 용도
2. 10-2023-0067542 (2023.05.25) 소리에 기반한 유전자 정보 표현 방법 및 시스템
3. 10-2022-0095927 (2022.08.02)
4. WO2022025502A1 (2022.02.03)
5. WO2022010241A1 (2022.01.03)
6. 2020-0095058 (2020. 07. 30)
7. 질환 세포-특이적인 miRNA에 의해 유도되는 세포 생리활성 조절 물질의 핵 내 전달용 운반체 및 이를 CRIPR/Cas9 시스템에 적용한 질환 특이적 유전자 조작용 복합체, 출원번호 2020-0083088 (2020. 07. 06)
8. 면역 세포 활성화를 통한 암 치료를 위한 RORα의 용도, 출원번호 2020-0064617 (2020. 05. 28)
9. Vegf-binding fragment mutant, and fusion protein comprising vegf-binding fragment mutant and anti-c-met antibody, WO2017/200173 A1
10. Biomarker DKK for predicting effect of c-Met inhibitor, WO2017/116064 A1
11. Method of screening an antibody, US2016/0161500 A1
12. Anti c-Met antibody and uses thereof, US2021/0269533 A1